Two pharma giants closed megadeals in the last week of March. Blackstone wrapped a new fund raise the same week.
The back half of Q1 tends to flush deals that have been in diligence since January. Two separate transactions in a single week means buyers aren’t sitting on the sidelines waiting for better terms or rate cuts. They’re paying full price, and they’re paying now.
Blackstone’s fund raise is the more consequential signal. When the largest alternative asset manager in the world closes a new fund, it’s a direct statement about where returns are expected: biopharma assets. More institutional dry powder chasing the same shortlist of acquisition targets doesn’t compress deal multiples — it inflates them. Sellers know it.
The question isn’t whether dealmaking continues. It’s whether mid-size biotechs can hold out for the premium they want, or whether they get outbid by funds with longer time horizons and deeper pockets than traditional pharma buyers.
Next catalyst to watch: who Blackstone backs first.
— Diana Kowalski